Motilal Oswal Maintains 'Buy' On Piramal Pharma Despite Near-Term Headwinds; Q2 Results Review

4 days ago 6

ARTICLE AD BOX

Motilal Oswal maintains a ‘Buy’ rating on Piramal Pharma and revises target price, implying a 20% upside.

07 Nov 2025, 07:07 PM IST i

07 Nov 2025, 07:07 PM IST

07 Nov 2025, 07:07 PM IST

<div class="paragraphs"><p>Piramal Pharma's revenue declined 9% YoY to Rs 20.4 billion (in line) for the quarter</p><p>(Photo source: Company website) </p></div>

Piramal Pharma's revenue declined 9% YoY to Rs 20.4 billion (in line) for the quarter

(Photo source: Company website)

Piramal Pharma delivered in-line revenue for Q2 FY62. However, it delivered a miss on Ebitda/PAT for the quarter. Higher operational costs impacted the quarter’s performance

To continue reading this story

You must be an existing Premium User

Already a Premium User?

Read Entire Article